BioCentury | Jul 30, 2018
Preclinical News

Apelin is a potential sarcopenia therapeutic

A paper in Nature Medicine suggests that apelin (APLN) could help treat sarcopenia as well as serve as a biomarker of the age-related disease characterized by skeletal muscle loss. Researchers from University of Toulouse and...
BioCentury | May 25, 2017
Emerging Company Profile

Total reprogramming

...cells (hESCs) and iPS cells into neurons, skeletal myocytes and oligodendrocytes by overexpressing Ngn2 , MYOD1...
...Mass. System Biosciences Inc., Palo Alto, Calif. University of Cambridge, Cambridge, U.K. Targets MYOD1 - Myogenic differentiation 1...
...skeletal myocytes, and oligodendrocytes." Stem Cell Reports (2017) Karen Tkach Tuzman, Senior Writer Elpis Biomed Ltd. Q-State Biosciences Inc. Myogenic differentiation 1 (MYOD1) Neurogenin...
BioCentury | Apr 18, 2017
Distillery Techniques

Disease models

...Also in engineered hPSCs, the combination of all- trans retinoic acid (ATRA) and overexpression of myogenic differentiation 1 (MYOD1)...
...Kotter, same affiliation as above email: mrk25@cam.ac.uk Hongjiang Li Elpis Biomed Ltd. University of Cambridge Fibroblast growth factor 2 (FGF2) Myogenic differentiation 1 (MYOD1) Neurogenin...
BioCentury | Oct 21, 2010
Tools & Techniques

ModeRNA approach to iPS cells

...differentiated somatic cells. Next, the group used modified mRNA encoding the myogenic transcription factor myogenic differentiation 1 (MYOD1...
BioCentury | Oct 14, 2010
Distillery Techniques

Technology: Drug platforms

...transcription factors. In newly produced iPS cells, modified mRNA encoding the myogenic transcription factor myogenic differentiation 1 (MYOD1...
BioCentury | Jan 7, 2010
Targets & Mechanisms

Targeting miRNAs in ALS

A team from The University of Texas Southwestern Medical Center at Dallas has identified a muscle-specific microRNA-miR-206-that plays a role in the progression of amyotrophic lateral sclerosis. 1 The results suggest that muscle cells could...
BioCentury | Oct 28, 1996
Clinical News

Paradigm Biosciences Inc. preclinical data

Paradigm presented mouse data showing an immune response to its vaccine, which was enhanced by a vitamin D3 adjuvant. The DNA vaccine uses a non-viral promoter specific to muscles. The gD2 gene of the virus...
Items per page:
1 - 7 of 7